BD (NYSE:BDX) announced today that it launched its next-generation glass prefillable syringe (PFS) for vaccine delivery. Franklin Lakes, New Jersey-based BD’s new Effivax syringe features tightened specifications for processability, cosmetics, contamination and integrity. The company designed it in collaboration with top pharmaceutical firms to meet the evolving needs of vaccine manufacturing. “As biopharmaceutical companies continue […]
BD
Analysts see multi-year transition to growth for Embecta
Embecta (Nasdaq:EMBC), the BD diabetes business spinoff, may take a few years to move into a growth phase, analysts say. BTIG analysts Marie Thibault and Sam Eiber wrote a report labeling Embecta as a “Neutral” option on the market. BD initially announced it would spin off its diabetes business in 2021, finally completing the move […]
BD wins patent fight against Baxter over drug-transfer system
BD (NYSE:BD) picked up a legal victory in a patent spat with Baxter (NYSE:BAX) over a system for moving drugs. A federal judge in Chicago ruled that BD’s PhaSeal system for transporting hazardous drugs between syringes and vials doesn’t infringe two patents belonging to Baxter. U.S. District Judge Joan Lefkow granted BD summary judgment on […]
Shareholder lawsuit over BD’s Alaris pumps recall moves forward
A federal judge in New Jersey is allowing part of a shareholder lawsuit to proceed against BD (NYSE: BDX) and CEO Thomas Polen over how they communicated company performance amid increasingly serious Alaris infusion pump problems. In an Aug. 11 opinion, Judge Stanley R. Chesler dismissed Industriens Pensionsforsikring’s claims against former BD CEO Vincent Forlenza […]
Embecta stock soars on first full-quarter results after BD spinoff
Embecta (Nasdaq: EMBC) today posted third-quarter results today for the first time as a BD (NYSE: BDX) spinoff, beating the consensus forecast on Wall Street. The Parsippany, New Jersey-based diabetes technology company reported profits of $62.4 million, or $1.08 per share, on sales of $291.1 million for the three months ended June 30. RELATED: How […]
BD warns on certain infusion systems due to potential leakage
BD (NYSE:BD) issued a notice in Europe to remove specific lots of its Connecta Stopcock and Nexiva with Connecta from use. In May, the Franklin Lakes, New Jersey-based company issued a product removal field safety notice and has since identified further lots which may also exhibit a reported defect. According to a notice dated July […]
BD buys MedKeeper and its connected pharmacy software for IV workflow
BD (NYSE:BD) announced today that it acquired cloud-based pharmacy management application developer MedKeeper. Franklin Lakes, N.J.-based BD said in a news release that MedKeeper strategically complements its existing presence in the pharmacy, with solutions for compounding, logistics workflow, controlled substance management and inventory optimization. MedKeeper’s platform will be made part of BD’s existing portfolio of […]
6 drug delivery innovations you need to know
From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops. Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies. More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With […]
BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for […]
How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD
Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to […]
